Page 2 - Genentech News Today

Recent health news includes drugmaker WuXi AppTec working with Chinese military scientists on altitude sickness treatments, FDA halting Biomea's diabetes trials due to liver toxicity, and a bird flu outbreak in Minnesota. Additionally, an antitrust probe into pharmaceutical companies over an eye drug and Novo Nordisk facing generic challenges in China are reported.

By Mary de Wet Relay Therapeutics will collaborate with Pfizer to study atirmociclib in combination with RLY-2608 and fulvestrant in patients with certain types of metastatic breast cancer. ...

Genentech sponsored a health equity symposium in partnership with the American Cancer Society and the University of Illinois Cancer Center over the weekend to underscore the need for health equity.

Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic...

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with...

English ...

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival (OS) rate of 69% and median overall survival (mOS) of 17.5 months in patients with previously treated PD-L1-positive

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive